FlexShopper Valuation
Is 9FL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 9FL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 9FL (€1.61) is trading above our estimate of fair value (€0.2)
Significantly Below Fair Value: 9FL is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 9FL?
Key metric: As 9FL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 9FL's PS Ratio? | |
|---|---|
| PS Ratio | 0.3x |
| Sales | US$134.56m |
| Market Cap | US$36.06m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 7.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 9FL's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 1x | ||
ALG ALBIS Leasing | 1.5x | n/a | €58.1m |
FRS FORIS | 0.5x | n/a | €12.3m |
EBEN aifinyo | 0.2x | n/a | €13.3m |
DFTK DF Deutsche Forfait | 1.9x | n/a | €17.6m |
9FL FlexShopper | 0.3x | 9.4% | €36.1m |
Price-To-Sales vs Peers: 9FL is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1.1x).
Price to Sales Ratio vs Industry
How does 9FL's PS Ratio compare vs other companies in the DE Diversified Financial Industry?
Price-To-Sales vs Industry: 9FL is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Diversified Financial industry average (1.9x).
Price to Sales Ratio vs Fair Ratio
What is 9FL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.3x |
| Fair PS Ratio | 1.5x |
Price-To-Sales vs Fair Ratio: 9FL is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.66 | €3.09 +86.0% | 23.1% | €3.80 | €2.37 | n/a | 2 |
| Nov ’25 | €1.13 | €2.56 +127.0% | 30.0% | €3.62 | €1.81 | n/a | 3 |
| Oct ’25 | €0.92 | €2.60 +183.7% | 30.0% | €3.66 | €1.83 | n/a | 3 |
| Sep ’25 | €0.96 | €2.60 +170.4% | 30.0% | €3.66 | €1.83 | n/a | 3 |
| Aug ’25 | €1.02 | €2.65 +159.8% | 30.0% | €3.74 | €1.87 | n/a | 3 |
| Jul ’25 | €1.19 | €2.65 +122.7% | 30.0% | €3.74 | €1.87 | n/a | 3 |
| Jun ’25 | €1.02 | €2.65 +159.8% | 30.0% | €3.74 | €1.87 | n/a | 3 |
| May ’25 | €0.93 | €2.65 +184.9% | 30.0% | €3.74 | €1.87 | n/a | 3 |
| Apr ’25 | €1.30 | €2.52 +94.0% | 38.6% | €3.90 | €1.83 | n/a | 3 |
| Mar ’25 | €1.12 | €2.52 +125.2% | 38.6% | €3.90 | €1.83 | n/a | 3 |
| Feb ’25 | €1.23 | €2.52 +105.1% | 38.6% | €3.90 | €1.83 | n/a | 3 |
| Jan ’25 | €1.54 | €2.52 +63.8% | 38.6% | €3.90 | €1.83 | n/a | 3 |
| Dec ’24 | €1.32 | €2.62 +98.7% | 41.6% | €4.17 | €1.85 | n/a | 3 |
| Nov ’24 | €0.94 | €2.62 +177.5% | 41.6% | €4.17 | €1.85 | €1.13 | 3 |
| Oct ’24 | €0.96 | €2.62 +173.2% | 41.6% | €4.17 | €1.85 | €0.92 | 3 |
| Sep ’24 | €0.89 | €2.62 +196.4% | 41.6% | €4.17 | €1.85 | €0.96 | 3 |
| Aug ’24 | €1.93 | €3.42 +77.1% | 35.8% | €5.13 | €2.33 | €1.02 | 3 |
| Jul ’24 | €1.18 | €3.42 +189.7% | 35.8% | €5.13 | €2.33 | €1.19 | 3 |
| Jun ’24 | €1.02 | €3.42 +235.1% | 35.8% | €5.13 | €2.33 | €1.02 | 3 |
| May ’24 | €0.70 | €3.54 +405.9% | 46.4% | €5.79 | €1.93 | €0.93 | 3 |
| Apr ’24 | €0.71 | €3.54 +397.4% | 46.4% | €5.79 | €1.93 | €1.30 | 3 |
| Mar ’24 | €0.96 | €3.54 +268.5% | 46.4% | €5.79 | €1.93 | €1.12 | 3 |
| Feb ’24 | €1.03 | €3.54 +245.2% | 46.4% | €5.79 | €1.93 | €1.23 | 3 |
| Jan ’24 | €0.83 | €3.54 +324.6% | 46.4% | €5.79 | €1.93 | €1.54 | 3 |
| Dec ’23 | €1.02 | €3.54 +248.6% | 46.4% | €5.79 | €1.93 | €1.32 | 3 |
| Nov ’23 | €1.66 | €4.50 +171.5% | 41.6% | €7.00 | €2.50 | €0.94 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
ORIX
JP¥3.8t
Provides diversified financial services in Japan, the United States, Asia, Europe, Australasia, and the Middle East.
OIX
JP¥20.40
7D
1.0%
1Y
22.2%
Exor
€20.6b
Engages in the luxury goods, automotive, agricultural and construction equipment, commercial vehicles, and professional football businesses worldwide.
EYX
€95.55
7D
2.9%
1Y
8.8%
Mutares SE KGaA
€484.6m
A private equity firm specializing in investments in secondary direct, special situations, bridge financing, recapitalization, distressed/vulture, management succession, reorganization, carve-outs, turnarounds, spin-offs and re-funding.
MUX
€22.40
7D
1.1%
1Y
-28.9%